Radwa Emam

Background:  Clostridium difficile infection (CDI) is a major cause of hospital acquired diarrhea, especially in the elderly and immunocompromised patients.^1,2 Clostridium difficile toxins, TcdA and TcdB, disrupt the actin cytoskeleton which leads to symptoms that range from mild diarrhea to fulminant colitis, toxic megacolon, shock, or kidney failure.¹ Standard antibiotics often fail to prevent recurrence of CDI, with relapse rates exceeding 25%.² Recurrent infections are associated with prolonged hospitalization, systemic inflammation, and increased mortality.^1,3,4 These therapies inadequately prevent relapse, particularly because they do not neutralize TcdA and TcdB which mediate colonic and systemic damage.^3,4 Currently, recurrent CDI remains a clinical challenge, with high rates of relapse despite antibiotic therapy and the variable efficacy of fecal microbiota transplantation (FMT).⁵ Monoclonal antibodies that neutralize C. difficile toxins offer a promising targeted approach by directly disrupting the pathogenic mechanism of infection.

Objective:  To evaluate the molecular mechanisms, immunologic impact, and clinical outcomes of monoclonal antibodies targeting C. difficile toxins, with a focus on bezlotoxumab, actoxumab, and PA41.

Search Methods:  A literature review was conducted using PubMed to identify relevant articles. Search terms included “Clostridium difficile,” “monoclonal antibody,” “bezlotoxumab,” “actoxumab,” “toxin A,” “toxin B,” “recurrent CDI,” and “toxin neutralization.” Studies examining molecular interactions, animal models, immune responses, and clinical efficacy were selected.

Results:  Studies showed that actoxumab binds the CROP domain of TcdA, blocking receptor interaction and enabling multivalent neutralization.⁶ PA41 targets a conserved region of TcdB’s glucosyltransferase domain which blocks intracellular toxin activity.⁷ Bezlotoxumab similarly inhibits TcdB mediated damage and reduces systemic inflammation.⁸ Animal models demonstrated that bezlotoxumab administration, both prophylactic and therapeutic, reduced organ damage and cytokine elevation, confirming the systemic protective effect of toxin neutralization.^6,8 Flow cytometry and histopathology confirmed that monoclonal antibody therapy preserves key immune responses, seen with neutrophil and eosinophil infiltration and IL-22 producing lymphoid cells, all while reducing excessive inflammation.⁹ Clinically, bezlotoxumab showed significantly reduced recurrence rates in high risk patients in a phase 3 trial by 26.6% without suppressing immunity or increasing adverse effects.¹⁰ These antibodies functioned not only as targeted antitoxins but also as adjuncts that support immune system recovery.

Conclusion:  Monoclonal antibody therapy, particularly bezlotoxumab, effectively prevents recurrent CDI by neutralizing the cytotoxic effects of TcdB. This strategy offers a promising alternative to antibiotic based approaches and redefines the previous therapeutic goal from microbial elimination to virulence factor neutralization. Findings from animal models and human trials demonstrate protection, minimal immune interference, and decreased risk of systemic complications. Future studies should explore earlier administration, combination with mucosal or immunostimulatory therapies, and expanded antibody engineering to address other toxin mediated diseases.

Works Cited:

1. Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211-1221. doi:10.1007/s10096-019-03539-6
2. Del Prete R, Ronga L, Addati G, et al. Clostridium difficile. A review on an emerging infection. Clin Ter. 2019;170(1):e41-e47. doi:10.7417/CT.2019.2106
3. Olmedo M, Kestler M, Valerio M, et al. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience. Rev Esp Quimioter. 2022;35(3):279-283. doi:10.37201/req/120.2021
4. Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723-750. doi:10.1093/femsre/fux048
5. Samarkos M, Mastrogianni E, Kampouropoulou O. The role of gut microbiota in Clostridium difficile infection. Eur J Intern Med. 2018;50:28-32. doi:10.1016/j.ejim.2018.02.006
6. Hernandez LD, Kroh HK, Hsieh E, et al. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab. J Mol Biol. 2017;429(7):1030-1044. doi:10.1016/j.jmb.2017.02.010
7. Kroh HK, Chandrasekaran R, Zhang Z, et al. A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells. J Biol Chem. 2018;293(3):941-952. doi:10.1074/jbc.M117.813428
8. Mileto SJ, Hutton ML, Walton SL, et al. Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection. Gut Microbes. 2022;14(1). doi:10.1080/19490976.2022.2117504
9. Denny JE, Alam MZ, Mdluli NV, Maslanka JR, Lieberman LA, Abt MC. Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection. Anaerobe. 2024;88:102859. doi:10.1016/j.anaerobe.2024.102859
10. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-317. doi:10.1056/NEJMoa1602615